Hologic (HOLX)
(Delayed Data from NSDQ)
$78.76 USD
-0.53 (-0.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $78.78 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.76 USD
-0.53 (-0.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $78.78 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Zacks News
Molecular Diagnostics to Aid Hologic's (HOLX) Q3 Earnings
by Zacks Equity Research
Strength in the Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) molecular diagnostics in Q3.
Hologic's New Panther Fusion System Gets Health Canada Nod
by Zacks Equity Research
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Hologic (HOLX) Down 1.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.
Medical Product Stock Earnings on May 2: CERN, ABC & More
by Zacks Equity Research
Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.
Can Higher System Sales Drive Cerner's (CERN) Q1 Earnings?
by Zacks Equity Research
Cerner's (CERN) Q1 earnings likely to reflect strength in System Sales and lucrative EHR prospects.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) Pharmaceutical business likely to put up a soft performance in Q3; raised guidance buoys optimism.
Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) likely to gain from core BD Medical segment and strategic buyouts.
Can Hologic (HOLX) Diagnostics Growth Recur in Q2 Earnings?
by Zacks Equity Research
A strong Panther system and an increasing utilization of Aptima women's health assays add stimulus to Global growth within Hologic's (HOLX) molecular diagnostics.
Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings?
by Zacks Equity Research
Pacific Biosciences gains ground on solid Sequel Growth, while shrinking service revenues raise concern.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q1 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) gains from EUROIMMUN buyout, solid guidance buoys optimism.
Can Business Services Aid athenahealth's (ATHN) Q1 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.
4 MedTech Stocks to Keep in Good Books This Earnings Season
by Zacks Equity Research
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
Hologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod
by Zacks Equity Research
Hologic (HOLX) forges ahead with initiatives to boost the Breast Health business.
Should Value Investors Consider Hologic (HOLX) Stock Now?
by Zacks Equity Research
Hologic (HOLX) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
Hologic (HOLX) Down 4.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic's Alliance With Philips to Boost Breast Health Unit
by Zacks Equity Research
Hologic (HOLX) is consistently trying to fortify its Breast Health segment.
Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical business boasts huge future prospects. Also, the recent commercial launch of MyoSure MANUAL device in the United States looks promising.
Hologic Banks on Diagnostics, GYN Surgical Prospects Bright
by Zacks Equity Research
Hologic (HOLX) stays upbeat about GYN Surgical on the recent commercial launch of MyoSure MANUAL device in the United States.
Hologic (HOLX) Q1 Earnings & Revenues Top, Margins Down
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Molecular Diagnostics, Breast Health and international business drives the top line in Q1.
CAH vs. HOLX: Which Will Fare Better This Earnings Season?
by Zacks Equity Research
Here we look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
Should You Sell Hologic (HOLX) Before Earnings?
by Zacks Equity Research
Hologic (HOLX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?
by Zacks Equity Research
Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.
Hologic (HOLX) Up 8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Hologic (HOLX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod
by Zacks Equity Research
Hologic's (HOLX) recent spree of regulatory approvals for its array of products is encouraging.